Acute Lymphoblastic Leukemia Complicated by Acute Severe Asthma - A Rare Finding:
A Case Report
Keywords:
Acute Lymphoblastic Leukemia, Acute Severe AsthmaAbstract
Introduction : The leukaemias are a group of disorders characterized by the accumulation of malignant white cells in the bone marrow and blood. These abnormal cells cause symptoms because of bone marrow failure and infiltration of organs; but acute severe asthma has not been reported as one of the manifestations/complications of acute lymphoblastic leukemia.
Objective: The aim of this paper is to briefly review the literature on acute lymphoblastic leukemia and its clinicopathologic relationship with asthma. A case of Acute Lymphoid leukemia being complicated by acute severe asthma is also reported.
Method/Result: I present a 36-year old male welder who came to the hospital with anaemic heart failure, leucocytosis and thrombocytopenia. Final diagnosis of acute lymphoblastic leukemia was made following bone marrow aspiration cytology and was subsequently commenced on chemotherapy. After successful Induction and Consolidation therapy, the patient had Acute Severe Asthmatic attack during the maintenance therapy and subsequently died in the hospital.
Conclusion: Acute Lymphoblastic Leukemia can be complicated by acute severe asthma. Early diagnosis and use of genuine cytotoxic drugs will go a long way to ameliorate the complications of Acute leukemia.gs gave variable results. Local injections with lidocaine were also successful. Refractory cases had surgical decompression.
Conclusion: Entrapment neuropathies were common conditions prevented by early identification and treatment.
References
Pui Ching-Hon. Acute lymphoblastic leukemia. In: kaushansky k, lichtman Ma, Beutler E, Kipps TJ, Seligsohn U, Prchal JT (eds), Williams Hematology, 8th edn, New York, McGraw Hill, 2010, pg 1409.
Pui CH, Relling MV, Downing JR. Acute Lymphoblastic leukemia. New Engl J Med 2004; 350: 1535-1541.
Pui CH, Robison LL, Look AT. Acute lymphoblastic leukemia. Lancet 2008; 371: 1030-1034.
Pui CH. Acute Lyphoblastic leukemia. In: childhood leukemia, 2nd edition, New York, Cambridge University press, 2006, pg 439.
Moricke A, Reiter A, Zimmermann M. Risk-adjusted therapy for ALL can decrease treatment burden and improve survival: treatment results of 2169 unselected paediatric and adolescent
patients enrolled in the trial ALL-BFM 95. Blood 2008; 111: 4477-4482.
Chessells JM, Hall E, Prentice HG et al. The impact of age on outcome in lymphoblastic leukemia, MRC UKALL X and XA compared. A report from the MRC paediatric and adult working parties. Leukemia 1998; 12: 463-467.
Hoelzer DF: Diagnosis and treatment of adult ALL. In: Wiernik PH, Canellos GP, Dutcher JP, Kyle RA(eds), Neoplastic diseases of the blood 3rd edn, New York, Churchill Livingstone, 1996,pg 295.
Larson RA, Dodge RK, Burns CP et al. A Five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia. Cancer and leukemia group B study 8811. Blood 1995; 85: 2025-2029.
Vogel G: New clues to asthma therapies. Science 1997; 276: 1643-1646.
Shelhamer J. airway inflammation in ALL. Ann Intern Med 1995; 123: 288-290
Costa JJ. The cells of the allergic response: mast cells, basophils and eosinophils. JAMA 1997; 278: 1815-1819
Crompton GK, Haslett C. diseases of the respiratory system. In: Edwards CRW, Bouchier IAD, Haslett C(eds). Principles and Practice of Medicine, 7th edn, Great Britain, Churchill Livingstone, 1995, pg 336.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
The data collected from registered and non-registered users of this journal falls within the scope of the standard functioning of peer-reviewed journals. It includes information that makes communication possible for the editorial process; it is used to informs readers about the authorship and editing of content; it enables collecting aggregated data on readership behaviors, as well as tracking geopolitical and social elements of scholarly communication.
This journal’s editorial team uses this data to guide its work in publishing and improving this journal. Data that will assist in developing this publishing platform may be shared with its developer Public Knowledge Project in an anonymized and aggregated form, with appropriate exceptions such as article metrics. The data will not be sold by this journal or PKP nor will it be used for purposes other than those stated here. The authors published in this journal are responsible for the human subject data that figures in the research reported here.
Those involved in editing this journal seek to be compliant with industry standards for data privacy, including the European Union’s General Data Protection Regulation (GDPR) provision for “data subject rights” that include (a) breach notification; (b) right of access; (c) the right to be forgotten; (d) data portability; and (e) privacy by design. The GDPR also allows for the recognition of “the public interest in the availability of the data,” which has a particular saliency for those involved in maintaining, with the greatest integrity possible, the public record of scholarly publishing.
